Study Overview
This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.
Description
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
Official Title
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study With an Extension to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis (ALAMERE)
Quick Facts
Study Start:2024-10-16
Study Completion:2027-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
| Inclusion Criteria | Exclusion Criteria |
|---|
| |
Contacts and Locations
Study Locations (Sites)
Research Site 1039
Dothan, Alabama, 36305
United States
Research Site 1037
Paradise Valley, Arizona, 85253
United States
Research Site 1018
Peoria, Arizona, 85306
United States
Research Site 1037
Scottsdale, Arizona, 85258
United States
Research Site 1003
Tucson, Arizona, 85715
United States
Research Site 1023
Englewood, California, 90301
United States
Research Site 1015
San Diego, California, 92120
United States
Research Site 1027
Bristol, Connecticut, 06010
United States
Research Site 1027
Cromwell, Connecticut, 06416
United States
Research Site 1040
Inverness, Florida, 34452
United States
Research Site 1001
Jacksonville, Florida, 32256
United States
Research Site 1007
Boise, Idaho, 83706
United States
Research Site 1048
Glenview, Illinois, 60026
United States
Research Site 1048
Gurnee, Illinois, 60031
United States
Research Site 1022
Iowa City, Iowa, 52242
United States
Research Site 1033
Topeka, Kansas, 66606
United States
Research Site 1032
Chevy Chase, Maryland, 20815
United States
Research Site 1004
Boston, Massachusetts, 02111
United States
Research Site 1013
Wyoming, Michigan, 49519
United States
Research Site 1006
Plymouth, Minnesota, 55446
United States
Research Site 1016
Reno, Nevada, 89511
United States
Research Site 1045
Freehold, New Jersey, 07728
United States
Research Site 1043
Jackson, New Jersey, 08527
United States
Research Site 1026
Chapel Hill, North Carolina, 27599
United States
Research Site 1021
High Point, North Carolina, 27265
United States
Research Site 1012
Columbus, Ohio, 43213
United States
Research Site 1020
Harrisburg, Pennsylvania, 17110
United States
Research Site 1014
Dallas, Texas, 75230
United States
Research Site 1008
Houston, Texas, 77494
United States
Research Site 1036
Pearland, Texas, 77584
United States
Research Site 1002
Ogden, Utah, 84405
United States
Research Site 1017
Sandy City, Utah, 84092
United States
Collaborators and Investigators
Sponsor: Uniquity One (UNI)
- Andrew W Lee, MD, STUDY_CHAIR, Vice President, Clinical Research
Study Record Dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
Study Start Date2024-10-16
Study Completion Date2027-08-31
Study Record Updates
Study Start Date2024-10-16
Study Completion Date2027-08-31
Terms related to this study
Additional Relevant MeSH Terms
- Eosinophilic Esophagitis (EoE)